Abstract
Temozolomide (Temodal®) an alkylating oral cytotoxic drug, has significantly improved overall survival of patients suffering from malignant brain tumours and has brought new initiative into the treatment of these tumours. Whereas Temozolomide (TMZ) is approved for the treatment of first-line glioblastoma and the relapse of glioblastoma and anaplastic glioma and is compassionately used in other settings including the first-line therapy of anaplastic glioma and low-grade gliomas and the relapse of low-grade gliomas, medulloblastomas/PNETs and primary CNS-lymphomas are frequently treated with TMZ in a compassionate setting, especially if they relapse. The various entities are currently undergoing different regimens. These will be discussed in detail.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
